Please ensure Javascript is enabled for purposes of website accessibility

Why Iovance Biotherapeutics Is Crashing Today

By James Brumley – Nov 18, 2022 at 1:06PM

Key Points

  • Iovance will be amending its rolling Biologics License Application for lifileucel early in the coming year.
  • The amendment requested by the FDA, however, should not be seen as a red flag.
  • No other drug currently directly addresses the niche of cancer patients that lifileucel does.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The FDA is asking the drug development outfit for more information regarding its tumor-infiltrating lymphocyte therapy.

What happened

Shares of biopharma company Iovance Biotherapeutics (IOVA -5.93%) are down 8.7% as of 12:31 p.m. ET Friday after the company announced it had received feedback from the U.S. Food and Drug Administration (FDA) regarding its new drug application for cancer treatment lifileucel. While the FDA's request for clarified information regarding the drug's effectiveness is in no way a rejection of lifileucel, it could potentially prolong the approval process.

But not by much.

So what

The FDA's feedback is more procedural than not. The regulator is simply looking for more "supplemental assay validation information and comparability data for lifileucel." In that its Biologics License Application for the therapy is a so-called rolling application that can be updated while it's being considered for approval, providing the requested information doesn't force the company to restart the licensing process for lifileucel once the data is collected. The company only has to amend its request. Iovance Biotherapeutics believes this entire addendum can be completed and submitted during the first quarter of the coming year.

If the news seems familiar, it may be because Iovance has reported similar news for lifileucel before. In May of last year, for instance, the FDA provided addressable feedback "regarding its potency assays for lifileucel." This request pushed the filing date for its Biologics License Application into 2022. For time perspective, the regulator confirmed and affirmed the updated assay data in April of this year, and the company submitted its rolling Biologics License Application -- the one the Food and Drug Administration responded to just this week -- in August. The seemingly lengthy span between these requests, their responses, and regulatory acknowledgment of these submissions is driving today's sell-off.

Now what

While agonizing for investors, it isn't unusual for companies to receive multiple requests for additional information during drug trials and after they submit New Drug Applications. Indeed, in some regard they clarify the path forward for biopharma outfits.

That's arguably the case here. That is, the FDA is telling Iovance what needs to be done in order to give its investigational tumor-infiltrating lymphocyte immunotherapy its best chance of an approval. And, given there are no other drugs specifically designed for melanoma patients who did not respond well to anti-PD-1/L1 or BRAF/MEK inhibitor therapies, those odds are already above average.

This still doesn't make it an appropriate pick for every portfolio. Even the most promising of biotech and biopharma companies are inherently risky, and should only be owned by investors who can stomach sizable losses should a pivotal drug fail to win the FDA's approval.

If you were willing to take such a risk on Iovance Biotherapeutics prior to today, though, only lifileucel's approval timeframe has changed in the meantime. This pullback is a buying opportunity for that particular crowd. 

James Brumley has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Iovance Biotherapeutics, Inc. The Motley Fool has a disclosure policy.

Stocks Mentioned

Iovance Biotherapeutics, Inc. Stock Quote
Iovance Biotherapeutics, Inc.
$6.75 (-5.93%) $0.42

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.